Advances in personalized medicine - Medicinal chemistry and pharmacology of vemurafenib and ivacaftor

Pharmazie

Volumn 68, Issue 7, 2013, Pages 484-491

  Pellowska, M ^a   Merk, D ^a   Schubert Zsilavecz, M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; IVACAFTOR; PLACEBO; SORAFENIB; VEMURAFENIB;

ALOPECIA; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; CYSTIC FIBROSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HIGH THROUGHPUT SCREENING; HUMAN; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN CARCINOMA; SURVIVAL RATE;

AMINOPHENOLS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYSTIC FIBROSIS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASES; QUINOLONES; SULFONAMIDES;

EID: 84882977077     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.6526     Document Type: Review

References (48)

1. Accurso FJ, Rowe SM, Clancy JP (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991-2003.
2. Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587-595.
3. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N (2012a) The role of BRAF V600 mutation in melanoma. J Transl Med 10: 85.
4. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N (2012b) Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: A possible algorithm for clinical use. J Transl Med 10: 107.
5. Atefi M,EuwEvon, Attar N,NgC, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A, Brandner JM (2011) Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE 6: E28973.
6. Atwell S, Brouillette CG, Conners K, Emtage S, Gheyi T, Guggino WB, Hendle J, Hunt JF, Lewis HA, Lu F, Protasevich II, Rodgers LA, Romero R, Wasserman SR, Weber PC, Wetmore D, Zhang FF, Zhao X (2010) Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. Protein Engin Design Select 23: 375-384.
7. Balakan O, Süner A, Yigiter R, Balakan T, Sirikçi A, Sevinç A (2012) Longterm survival in metastatic malignant melanoma: Ipilimumab followed by vemurafenib in a patient with brain metastasis. InternMed51: 2819-2823.
8. Barrett PM, Alagely A, Topol EJ (2012) Cystic fibrosis in an era of genomically guided therapy. Human Mol Genet 21 (R1): R66-71.
9. Bollag G, Hirth P, Tsai J. Zhang J, Ibrahim PN, Cho H, SpevakW, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KYJ, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K,Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, FlahertyKT,XuX, Nathanson KL, NolopK(2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467 (7315): 596-599.
10. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P (2012) Vemurafenib: The first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11: 873-886.
11. Bompadre SG, LiM,HwangTC(2007) Mechanism of G551D-CFTR(cystic fibrosis transmembrane conductance regulator) potentiation by a high affinity ATP analog. J Biol Chem 283: 5364-5369.
12. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367: 2316-2321.
13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, FlahertyKT, McArthurGA(2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
14. Comer D, Ennis M, McDowell C, Beattie D, Rendall J, Hall V, Elborn J (2009) Clinical phenotype of cystic fibrosis patients with the G551D mutation. QJM 102: 793-798.
15. Davis MJ, Schlessinger J (2012) The genesis of zelboraf: Targeting mutant B-Raf in melanoma. J Cell Biol 199: 15-19.
16. Davis PB,Yasothan U, Kirkpatrick P (2012) Ivacaftor. Nat Rev Drug Discov 11: 349-350.
17. Eckford PDW, Li C, Ramjeesingh M, Bear CE (2012) Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylationdependent butATP-independent manner. J Biol Chem 287: 36639-36649.
18. Finn L, Markovic SN, Joseph RW(2012) Therapy for metastatic melanoma: The past, present, and future. BMC Med 10: 23.
19. Fisher R, Larkin J (2012) Vemurafenib: A new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res 4: 243-252.
20. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
21. Flaherty KT, Yasothan U, Kirkpatrick P (2011) Vemurafenib. Nat Rev Drug Discov 10: 811-812.
22. Flume PA (2012) Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation Chest 142: 718-724.
23. Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O,Wong ET (2012) Melanoma brain metastasis: Overview of current management and emerging targeted therapies. Expert Rev Neurother 12: 1207-1215.
24. Galfrè E, Galeno L, Moran O (2012) A potentiator induces conformational changes on the recombinant CFTR nucleotide binding domains in solution. Cell Mol Life Sci 69: 3701-3713.
25. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M (2010) PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell Melanoma Res 23: 190-200.
26. Heakal Y, Kester M, Savage S (2011) Vemurafenib (PLX4032): An orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother 45: 1399-1405.
27. Hudson RP, Chong PA, Protasevich II, Vernon R, Noy E, Bihler H, An JL, Kalid O, Sela-Culang I, Mense M, Senderowitz H, Brouillette CG, Forman-Kay JD (2012) Conformational changes relevant to channel activity and folding within the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 287: 28480-28494.
28. Inamdar GS, Madhunapantula SV, Robertson GP (2010) Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochem Pharmacol 80: 624-637.
29. Kaplan FM, Mastrangelo MJ, Aplin AE (2010) The wrath of RAFs: Rogue behavior of B-RAF kinase inhibitors. J Investig Dermatol 130): 2669-2671.
30. Lemech C, Arkenau HT (2012) Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 6: 53-66.
31. Lewis H,Wang C, Zhao X, HamuroY, Conners K,Kearins M, Lu F, Sauder J, Molnar K, Coales S, Maloney P, GugginoW,Wetmore D,Weber P, Hunt J (2010) Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. J Mol Biol 396: 406-430.
32. Lubamba B, Dhooghe B, Noel S, Leal T (2012) Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 45: 1132-1144.
33. Luke JJ, Hodi FS (2012) Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma. Clin Cancer Res 18: 9-14.
34. Melin P, Norez C, Callebaut I, Becq F (2006) The glycine residues G551 and G1349 within the ATP-binding cassette signature motifs play critical roles in the activation and inhibition of cystic fibrosis transmembrane conductance regulator channels by phloxine B. J Membrane Biol 208: 203-212.
35. Mello RA de (2012) Metastatic melanoma and vemurafenib: Novel approaches. Rare Tumors 4: E31.
36. Moran O (2010) Model of the cAMP activation of chloride transport by CFTR channel and the mechanism of potentiators. J Theor Biol262: 73-79.
37. Pasyk S, Li C, Ramjeesingh M, Bear CE (2009) Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease. Biochem. J. 418: 185-190.
38. PDB ID (2014) : 3OG7.
39. Pyle LC, Ehrhardt A, Mitchell LH, Fan L, Ren A, Naren AP, Li Y, Clancy JP, Bolger GB, Sorscher EJ, Rowe SM (2011) Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators. AJP: Lung Cell Mol Physiol 301: L587.
40. RamseyBW, Davies J, McElvaney NG, Tullis E, Bell SC,Drevínek P, Griese M,McKone EF,Wainwright CE,KonstanMW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365: 1663-1672.
41. Shi H, Kong X, Ribas A, Lo RS (2011) Combinatorial treatments that overcome PDGFR-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71: 5067-5074.
42. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714.
43. Su F, Bradley WD,Wang Q,Yang H, Xu L, Higgins B,KolinskyK, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G (2012) Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 72: 969-978.
44. Tuma RS (2011) Getting around PLX4032: Studies turn up unusual mechanisms of resistance to melanoma drug. J Nat Cancer Inst 103: 170-177.
45. van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106: 18825-18830.
46. Wang W, Wu J, Bernard K, Li G, Wang G, Bevensee MO, Kirk KL (2010) ATP-independent CFTR channel gating and allosteric modulation by phosphorylation. Proc Nat Acad Sci 107: 3888-3893.
47. Wellbrock C, Hurlstone A (2010) BRAF as therapeutic target in melanoma. Biochem Pharmacol 80: 561-567.
48. Zhang C, Bollag G (2010) Scaffold-based design of kinase inhibitors for cancer therapy. Current Opin Genet Dev 20: 79-86.